Division of hematology / oncology

Research

Yubin Kang, M.D.

Assistant Professor
Division of Hematology-Oncology
Department of Medicine
Hollings Cancer Center
Medical University of South

Education:

Dr. Kang received his medical degree from the Shanghai Second Military Medical University (China). He did his residency training in internal medicine at the University of Iowa Hospitals and Clinics, and completed his fellowship in Hematology-Oncology at Duke University Medical Center.

Contact Information:

Hollings Cancer Center
A National Cancer Institute Designated Cancer Center
Room HO307
86 Jonathan Lucas St.
Charleston, SC 29425
Tel: 843 792 6520
Fax: 843 792-0644
Email: kangy@musc.edu

U.S. Board Certification:

2007-2017Internal Medicine
2010-2020Hematology
2010-2020Medical Oncology
Lab Members:

Ningfei An, PhD., Postdoctoral Fellow

Amr Abdallah Moh `D Qudeimat, Pediatrics Hematology-Oncology Fellow

Research Interests:

I am pursuing a physician scientist academic career and my goal is to translate research findings obtained from the laboratory into patient directed care. My clinical practice focuses on hematopoietic stem cell transplantation and hematological malignancies in particular multiple myeloma.  My research interests are on 2 main areas: exploring CXCR4 antagonists for enhanced donor hematopoietic cell recovery and developing novel therapeutic agents for the treatment of multiple myeloma.

CXCR4 is a chemokine receptor and is expressed on many cell types.  The interaction between CXCR4 and its ligand, stromal derived factor -1 (SDF-1), plays an indispensable role in hematopoietic stem cell (HSC) homing, engraftment and proliferation.  We recently found that post-transplant administration of a CXCR4 antagonist (i.e., plerixafor, also called AMD3100) improved animal survival and enhanced donor cell recovery (Kang et al, PloS ONE, 5(6):e11316).  My currently ongoing efforts are: 1) to understand the molecular mechanisms underlying HSC homing, mobilization and expansion; 2) to investigate the biological crosstalk between CXCR4 receptor and SDF-1 and its signaling pathway; 3) to explore the therapeutic utilities of CXCR4 antagonists in enhancing donor cell engraftment in reduced intensity transplant and in T cell-depleted transplant model; and 4) to perform a phase I/II clinical trial to test the safety and efficacy of plerixafor in enhancing donor cell engraftment in myeloablative allogeneic transplant patients.

My other area of research interest is to develop novel therapeutic agents for the treatment of multiple myeloma. Multiple myeloma is the second most common hematological malignancy in the United States. Despite the wide use of several highly effective chemoagents (i.e., Thalidomide, Lenalidomide and Bortezomib) and the incorporation of autologous hematopoietic stem cell transplant, multiple myeloma remains an incurable disease, suggesting the need for better understanding the disease pathogenesis and for developing novel agents.  My laboratory has been exploring the role of Pim (proviral insertion in murine lymphoma) serine/threonine kinases in multiple myeloma.  We recently found that Pim kinases were highly expressed in myeloma cell lines and in CD138 primary myeloma cells. Targeting Pim kinases using small molecule Pim kinase inhibitors induced apoptotic cell death in myeloma cells.  My currently ongoing efforts are: 1) to further define the role of Pim kinases in the pathogenesis of multiple myeloma; 2) to measure Pim kinase expression in myeloma patients and correlate the expression level with disease status and treatment responses; 3) to understand Pim kinase downstream signaling pathways in multiple myeloma; and 4) to test the efficacy and safety of Pim kinase inhibitors in multiple myeloma animal models.

Publications: 

1.      Yeong-Bin Im, Ying-Wei Lin, Ningfei An, Cristina Gasparetto, Zanna M. Beharry, Jin H. Song, Bei Liu; Zihai Li, Charles Smith, Andrew S. Kraft, and Yubin Kang. 2011. “Pim serine/threonine kinases as a novel target for the treatment of multiple myeloma”. (submitted).
2.      Yubin Kang, Benny J. Chen, Divino DeOliveria, Jeff Mito and Nelson J. Chao. 2010 “Selective enhancement of donor hematopoietic cell engraftment by the CXCR4 antagonist AMD3100”. PLOS ONE, 2010 Jun 28;5(6):e11316.
3.      Yubin Kang, Nelson J. Chao and Franco Aversa. 2008. “Unmanipulated or CD34 selected haplotype mismatched transplants”. Curr Opin Hematol. 15:561-567.
4.      Yubin Kang, Todd E. Scheetz, Christopher J. Moressi, Diane Thi Tran, Litao Xie, Beverly L. Davidson, Thomas L Casavant, and Paul B. McCray Jr. 2006. “Integration site choice of a feline immunodeficiency virus vector”.J Virol. 2006 Sep;80(17):8820-3.
5.      Yubin Kang, Litao Xie, Diane Thi Tran, Melissa Hickey, Colleen S. Stein, Beverly L. Davidson, and Paul B. McCray, Jr. 2005. “Persistent expression of factor VIII in vivo following nonprimate lentiviral gene transfer”. Blood. 2005 September 1; 106(5):1552-1558 (University of Iowa News Release on 8/23/05: Gene therapy advance treats hemophilia in mouse models).
6.      L. Song, J. Wang, R. Wang, M. Yu, Y. Sun, G. Han, Y. Li, J. Qian, DW Scott, Y. Kang, N. Soukhareva, and B. Shen. 2004. “Retroviral delivery of GAD-IgG fusion construct induces tolerance and modulates diabetes: a role for CD4+ regulatory T cells and TGF-beta?” Gene Ther. 2004 Oct; 11 (20):1487-96.
7.      Timothy D. Starner, Carrie K. Barker, Hong Peng Jia, Yubin Kang, and Paul B. McCray Jr. 2003. “CCL20 is an inducible product of human airway epithelia with innate immune properties.” Am J Respir Cell Mol Biol. 29(5):627-33. Epub 2003 May 14
8.      Yubin Kang*, Colleen S. Stein*, Jason A. Heth, Patrick L. Sinn, Andrea K. Penisten, Patrick D. Staber, Hong Shen, Carrie K. Barker, Inês Martins, C. Matthew Sharkey, David Avram Sanders, Paul B. McCray, Jr., and Beverly L. Davidson. 2002. “In Vivo Gene Transfer using a Nonprimate Lentiviral Vector Pseudotyped with Ross River Virus Glycoproteins”. J. Virol. 76: 9378-9388 (*-- co-first authors) (press releases in ScienceDaily Magazine, http://www.sciencedaily.com/releases/2002/10/ 021010065528.htm)
9.     Marco E.F. Melo, Jiahua Qian, Moustapha El-Amine, Nadejda Soukhareva, Yubin Kang, and David W. Scott, 2002, “Gene transfer of immunoglobulin-fusion proteins prevents and treats autoimmune diseases”. J. Immunol. 168:4788-4795.
10. Colleen S. Stein*, Yubin Kang*, Sybille L. Sauter, Kay Townsend, Patrick Staber, Todd A. Derken, Inês Martins, Jiahua Qian, Beverly L. Davidson, and Paul B. McCray, Jr., 2001, “ In vivo treatment of hemophilia A and mucopolysaccharidosis type VII using non-primate lentiviral vectors”. Molecular Therapy. 3:850-856. (* co-first authorship).
11. Moustapha El-Amine, Marco Melo, Yubin Kang, Jiahua Qing and David W. Scott, 2000, “Mechanisms of tolerance induction by an Ig-peptide molecule expressed and secreted by B cells”. J. Immunol. 165:5631-5636.
12.  Rajeev Agarwal, Yubin Kang, Elias Zambidis, David W. Scott, C. C. Chan and Rachel Caspi, 2000, “Retroviral gene therapy with an immunoglobulin-antigen fusion construct protects from experimental autoimmune uveitis”. J. Clin. Invest. 106:245-252. (Commentary by George C. Tsoko and Gerald T. Nepom, “Gene therapy in the treatment of autoimmune diseases”, J. Clin. Invest. 106:181-183).
13.  Yubin Kang, Marco Melo, Roland Tisch, Edward Deng and David W. Scott, 1999, “Induction of hyporesponsiveness to intact foreign protein via retroviral-mediated gene expression: the IgG scaffold is important for induction and maintenance of immune hyporesponsiveness”, Proc. Natl. Acad. Sci, USA,  96:8609-8614.
14.  Yubin Kang, Marco Melo and David W. Scott, 1998, “An Ongoing Immune Response to HIV Envelope gp120 in Human CD4 Transgenic Mice Contributes to T Cell Decline upon Intravenous Administration of gp120”, Eur. J. Immunol., 28:2253-2264
15.  Paul J. Thornalley, Muhati Ladan, Simon Ridgeway and Yubin Kang, 1996, “ Anti-tumor Activity of S-(p-bromobenzyl)glutathione Diesters in vitro: a Structure-Activity Study”, J. Med. Chem., 39(17):3409-11
16.  Yubin Kang, Linda Edwards and Paul J. Thornalley, 1996, “Effect of Methylglyoxal on Human Leukemia 60 Cell Growth: Modification of DNA, G1 Growth Arrest and Induction of Apoptosis’, Leukemia Research, 20(5):397-405
17.  Paul J. Thornalley, Linda Edwards, Yubin Kang, C. Wyatt, N. Davies, M. J. Ladan and J. Double, 1996, “ Anti-tumor Activity of S- (p-bromobenzyl)glutathione Cyclopentyl Diesters In Vitro and In Vivo: Inhibition of Glyoxalase I and Induction of Apoptosis”, Biochemical. Pharmacology, 51(10):1365-72 

Book Chapters:

1.      Yubin Kang and Nelson J. Chao. 2011. “Strategies to enhance hematopoietic stem cell engraftment following transplantation”, In: Fruehauf eds. “Novel developments in stem cell mobilization: focus on CXCR4”. Springer New York.
2.      Yubin Kang and Nelson J. Chao. 2009. “Immune reconstitution”, In: Wingard JR, Gastineau D, Leather H, Snyder EC, Szczepiokowski ZM, eds. “Hematopoietic Stem Cell Transplantation: A Clinician’s Handbook”. Bethesda, MD, AABB Press, p181-196.
3.      Yubin Kang and Yubao Cheng, 1996, “Interleukin-3”, In: He Jiang and Wang Dong Xian, Eds. A Handbook of Human Cytokines, Tong Zi University Press, p79-96.
4.      Yubin Kang and He Jiang, 1996, “Interleukin-4”, In: He Jiang and Wang Dong Xian, Eds. A Handbook of Human Cytokines, Tong Zi University Press, p97-112. 


Research Support:

MUSC Holllings Cancer Center Startup Fund07/01/2010-06/30/2014
Role: PI
Hollings Cancer Center ACS IRG01/01/2011-12/30/2011
Exploring β-2 adrenergic receptor in acute myelogeous leukemia
Role: PI

Conquer Cancer Foundation (ASCO) Career Development Award

07/01/2011-06/30/2014

A phase I/II study: enhancing donor cell recovery with CXCR4 antagonists in hematopoietic cell transplantation

Role: PI



News:

Dr. Kang received one of only ten 2011 American Society of Oncology (ASCO) Career Development Awards for his project entitled," A PhaseI/II Study: Enhancing Donor Cell Engraftment with CXCR4 Antagonist in Hematopoietic Stem Cell Transplantation."
This is a very prestigious and competitive award that provides research funding to junior clinical investigators to establish an independent clinical cancer research program. Initiated in 1992, the Career Development Award Program began with four individuals receiving grants. To date, 189 investigators have received grants through this program, generally fewer than 15 annually.

 

 
 
 

© Medical University of South Carolina | 171 Ashley Avenue, Charleston, SC 29425